OneDigital Investment Advisors LLC Purchases 180 Shares of Zoetis Inc. (NYSE:ZTS)

OneDigital Investment Advisors LLC raised its position in Zoetis Inc. (NYSE:ZTS) by 3.0% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 6,245 shares of the company’s stock after acquiring an additional 180 shares during the period. OneDigital Investment Advisors LLC’s holdings in Zoetis were worth $1,220,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Sarasin & Partners LLP grew its holdings in shares of Zoetis by 546.3% in the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after acquiring an additional 1,904,899 shares in the last quarter. Swedbank AB bought a new position in Zoetis during the first quarter worth about $210,815,000. International Assets Investment Management LLC lifted its position in shares of Zoetis by 41,235.7% in the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock valued at $183,652,000 after buying an additional 937,700 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Zoetis by 7,608.6% during the 2nd quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after acquiring an additional 824,843 shares during the period. Finally, Canada Pension Plan Investment Board lifted its holdings in Zoetis by 178.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 639,352 shares of the company’s stock valued at $108,185,000 after purchasing an additional 409,522 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 0.7 %

Shares of ZTS opened at $176.42 on Tuesday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The stock has a fifty day moving average of $186.78 and a 200-day moving average of $180.45. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a market capitalization of $79.59 billion, a price-to-earnings ratio of 33.16, a PEG ratio of 2.69 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the business earned $1.36 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is currently 32.33%.

Analysts Set New Price Targets

Several analysts recently commented on ZTS shares. Stifel Nicolaus lifted their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. upped their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. BTIG Research lifted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Piper Sandler raised their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.